These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7545340)

  • 41. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

  • 42. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
    Colli JL; Amling CL
    Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Opportunity for a systematic screening of prostatic cancer by determining prostate specific antigen levels].
    Cuzin B; Maisonneuve H; Thoral F; Charvet-Protat S
    Prog Urol; 2000 Feb; 10(1):124-7. PubMed ID: 10785932
    [No Abstract]   [Full Text] [Related]  

  • 44. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA; Kuriyama M
    Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prostate carcinoma. What does PSA screening bring?].
    Schultze-Seemann W
    MMW Fortschr Med; 2005 Nov; 147(45):13. PubMed ID: 16320645
    [No Abstract]   [Full Text] [Related]  

  • 46. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate cancer options expand beyond the PSA.
    Clin Resour Manag; 2002 May; 3(5):65-8. PubMed ID: 12048767
    [No Abstract]   [Full Text] [Related]  

  • 48. [The evaluation of the ratio of free and total serum prostate-specific antigen as an additional method in the diagnosis of prostatic cancer].
    Reznikov IuP; Mazanov GP; Sedova TN
    Urol Nefrol (Mosk); 1996; (6):41-3. PubMed ID: 9036610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer.
    Boscolo-Berto R
    Int J Urol; 2009 Sep; 16(9):711. PubMed ID: 19769655
    [No Abstract]   [Full Text] [Related]  

  • 50. [The percentage of free prostate specific antigen used in detecting prostate cancer].
    Yang L; Fang Z; Song J; Deng S
    Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The PSA revisited: potentials and pitfalls.
    Harv Mens Health Watch; 1999 Jun; 3(11):1-5. PubMed ID: 10233802
    [No Abstract]   [Full Text] [Related]  

  • 52. Screening for prostate cancer: who and how often?
    Schwartz K; Deschere B; Xu J
    J Fam Pract; 2005 Jul; 54(7):586-96. PubMed ID: 16009085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
    Zhao XJ; Kong XB; Wang WH
    Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The case for prostate cancer screening.
    Andriole GL
    Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate cancer and prostate specific antigen. A Jamaican perspective.
    Douglas LL
    West Indian Med J; 1999 Jun; 48(2):47-9. PubMed ID: 10492600
    [No Abstract]   [Full Text] [Related]  

  • 56. Prostate cancer in the serum prostate-specific antigen era.
    Humphrey PA
    Mayo Clin Proc; 1998 May; 73(5):489-90. PubMed ID: 9581595
    [No Abstract]   [Full Text] [Related]  

  • 57. Screening for prostatic disease.
    Gupta S; Pound CR
    J Miss State Med Assoc; 2013 Sep; 54(9):255-7. PubMed ID: 24371903
    [No Abstract]   [Full Text] [Related]  

  • 58. Prostate-specific antigen screening for prostate cancer: why so much controversy?
    Labrie F
    Int J Urol; 2013 Nov; 20(11):1148. PubMed ID: 23586435
    [No Abstract]   [Full Text] [Related]  

  • 59. The controversy of prostate screening.
    McDougall GJ; Weber BA; Dziuk TW; Heneghan R
    Geriatr Nurs; 2000; 21(5):245-8; quiz 249. PubMed ID: 11035306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate cancer screening: an innovative approach to accrual of large numbers of patients with early stage disease.
    Levine PA; Urich V; Murphy B; Parzinski R
    Prog Clin Biol Res; 1986; 216():79-85. PubMed ID: 2425374
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.